Ovarian Cancer News & Features
A method to determine which patients with ovarian cancer are more likely to respond well to the new anticancer drug rucaparib has been discovered.
Ovarian clear cell adenocarcinoma (CCA), a rare and aggressive form of ovarian cancer, may be treated by employing pelvic radiotherapy (RT).
A new approach to treatment using a cancer-killing virus combined with a chemotherapy drug may offer hope to those with advanced and recurrent forms of metastatic ovarian cancer.
Olaparib, an experimental oral cancer drug, has shown an overall tumor response rate of 26% in advanced cancers associated with BRCA1 and BRCA2 mutations, according to recent research.
FDA has approved Avastin (bevacizumab) for treatment of platinum-resistant recurrent epithelial ovarian cancer.
Ovarian Cancer Clinical Trials
- Key discovery in understanding successes and failures of immunotherapy
- Researchers identify biological indicator of response to new ovarian cancer drug
- Managing obesity should be part of cancer care
- Galeterone active in one form of castration-resistant prostate cancer
- Reducing side effects of everolimus administration
- Navigation and survivorship: Rationalizing your program costs
- Monitoring psychosocial function in radiotherapy
- Comparison of medications for managing nausea and vomiting
- Comparison of constipation management medications
- Chemo- and immunotherapy combination is a promising treatment for pancreatic cancer
- High tumor immune cell levels may identify women with HER2+ breast cancer who may benefit from chemotherapy alone
- Hair Dyes and Cancer Risk (Fact Sheet)
- For bladder cancer, laparoscopic radical cystectomy effective at preventing recurrence
- Aspirin and/or NSAID use may improve risk of high-grade prostate cancer
- Modifying lifestyle, HPV vaccine can help prevent anal cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|